Murdoch loses bid to change trust in 'Succession' battlePushpa 2 Kissik Not Even 1 Percent Of Oo Antava: Netizens Call Sreeleela-Allu Arjun Song A Downgrade

A STUNNING farm with views of the ''only lake in Scotland'' has hit the market. The 446-hectare upland hill farm sits in an area unique to Scotland . 3 The upland farm overlooks the only lake in Scotland, Lake Menteith Credit: SWNS 3 It also contains the ruins of an old shepherd's cottage Credit: SWNS 3 And it includes more than 440 hectares of land Credit: SWNS Situated in Stirlingshire, it overlooks the only body of water in the country referred to as a 'lake'. This is believed to be because of the 1838 UK Government 's Ordnance Survey , who mapped the area for the first time, identified it as a lake, rather than the typical 'loch.' Glenny Hill farm is described as "an idyllic and beautiful part of rural Stirlingshire," which sits on the banks of Lake Menteith. The farmland reaches 427m above sea level at its highest point, providing panoramic views over the water. READ MORE ON THE SCOTTISH SUN SNOW END Storm Bert develops into Atlantic weather bomb due to go off across Scotland TAN CAM RAID Scots Turkish barbers raided after 'sunbed spy cam' discovered in shop Land for Chartered Land and Forestry Agency described the opportunities for potential owners to graze cattle, introduce horses , or even take part in sustainable deer stalking. The listing reads: "Glenny Hill was traditionally managed for the grazing of sheep and cattle for many years with old stone dykes (walls) separating field units in the past and more recently the use of stock fences to manage livestock on the lower lying improved grassland or inbye as it is known. "Part of Glenny Hill was planted 20 - 30 years ago to create both mixed and native species woodland which has established well and now creates shelter, a source of fuel wood and significant amenity value. "The current owner has managed Glenny Hill Farm on a contract farming arrangement, grazing 35 head of highland and highland/short horn mix breeding cattle. Most read in Money HELPING CASH Exact date all Winter Heating Payment should be paid by GOING GONE Cadbury confirms it has discontinued a popular Christmas chocolate bar FESTIVE FIZZ Coca-Cola Christmas truck in Scotland: Dates, locations & all you need to know JOBS JOY Scottish Power to create 1,000 new jobs with £5billion amid modernisation scheme "The cattle have helped to improve the land with conservation grazing, breaking down the Bracken, creating a diverse mosaic of habitats on the inbye, within the woodland and out on the higher hill ground in summer ." Sheep and horses could be added to the farm as the land boasts a great potential for "pony trekking to be enjoyed". 195-acre estate in heart of Lake District with farm, tea rooms and glamping business on market for £2.25m Already teeming with wildlife , Red and Roe deer are known to graze parts of the farm - offering the opportunity for "deer stalking and a fresh supply of fresh venison." Containing the ruins of an old shepherd's cottage and with planning permissions for a house next to them, the property offers the potential for the landowner to reside on the farm. Prospective buyers can build a farmhouse that would provide a prime location for a secluded cabin in an idyllic setting. Though there are currently no services on the farm, mains electricity and telephone lines service the nearby properties. The listing continues: "A private water supply would be possible via a spring fed bore hole and there would also be potential for solar and wind power if looking for a truly off grid and sustainable development opportunity, subject to firstly obtaining planning consent. "Glenny Hill farm now offers a rare opportunity to enhance a diverse range of habitats as well as creating a lovely manageable farm or small estate for future enjoyment." Glenny Hill farm is now up for sale for offers over £1.4m.What we know about Luigi Mangione, person of interest in UnitedHealthcare CEO's murder

Researchers launch “moonshot” to cure blindness through eye transplantsA well-organised school assembly sets a positive tone for the day, inspiring students and fostering a sense of unity. This guide provides everything you need to make your assembly engaging and impactful: from current news highlights to motivational thoughts for the day, and a well-crafted anchoring script. Let’s dive into the essential components for hosting a memorable assembly. Mumbai: A well-organised school assembly sets a positive tone for the day, promoting unity and enthusiasm within the school community. This guide provides a comprehensive approach to planning and delivering impactful assemblies, covering key elements like current news updates, motivating thoughts for the day, and a flexible anchoring script. With these resources, creating a dynamic and meaningful event becomes a seamless task. School assemblies play a crucial role in the holistic development of students, offering a platform to cultivate leadership skills, build self-confidence, and strengthen community ties. They are more than just routine events; they provide valuable opportunities for collaboration, learning, and inspiration, becoming an essential part of a vibrant educational environment. The success of an assembly relies on careful planning and creative input. By blending educational, motivational, and entertaining elements, educators can craft sessions that engage students and leave a lasting impact. The process starts with selecting a theme that resonates with the students, aligns with the school’s values, or highlights important events and upcoming celebrations. A well-selected theme sets the tone and direction for the assembly. Starting with a warm, energetic welcome creates a welcoming atmosphere and encourages participation. Introducing a Thought of the Day offers a chance for reflection, motivating students with optimism and self-awareness. This can be followed by brief updates on school activities, achievements, or global news to keep students informed and connected. Including interactive activities like performances, role-plays, or quizzes adds excitement and encourages active student participation. These activities not only highlight student talents but also help develop public speaking and teamwork skills. As the assembly wraps up, recognising contributions, sharing important announcements, and concluding with a collective gesture—such as singing the national anthem, reciting the school pledge, or delivering a motivational message—helps foster pride and unity. To make the assembly memorable, ensure each segment is concise and engaging, holding the audience’s attention. Promoting inclusivity and valuing each student’s presence enhances the experience, leaving a positive, lasting impact. With thoughtful planning and effective execution, school assemblies can become transformative events that inspire, strengthen connections, and create cherished memories for everyone involved. Tips for hosting a successful school assembly: Engage the audience: Speak with enthusiasm and clarity to capture attention and maintain interest throughout the assembly. Practice and rehearse: Conduct rehearsals to ensure participants are comfortable and confident, minimizing errors on the day. Incorporate visual aids: Use tools like projectors, charts, or slides to enhance the presentation and make the assembly visually engaging. Manage time effectively: Stick to the planned schedule to keep the assembly concise and respect everyone’s time. Encourage active participation: Invite students to share ideas, perform, or participate in interactive activities to foster ownership and involvement. Thought for the Day for school assembly “Sometimes the most productive thing you can do is relax and recharge.” School assembly news headlines today Refer to the top school assembly headlines covering national, international, and sports news: National news for school assembly International news for school assembly Sports news for school assembly Anchoring Script for School Assembly Here’s an engaging and lively anchoring script for a school assembly—a perfect mix of warm greetings, inspirational thoughts, news updates, motivational moments, and an exciting performance. Crafted to captivate and energise, this script guarantees a memorable and impactful experience for everyone involved. [Opening Remarks] Anchor 1: Good morning, everyone! A warm welcome to our respected Principal, dedicated teachers, and all our wonderful students. I’m [Anchor Name], and I’m thrilled to guide you through today’s assembly. Let’s start the day on a high note! Anchor 2: Good morning! It’s fantastic to see so many bright and eager faces ready to kick off the day with positive energy and purpose. We have an exciting program ahead, so let’s dive right in! [Thought for the Day] Anchor 1: To set the tone for the day, let’s begin with an inspiring thought. [Student Name], please share today’s thought. Anchor 2: Thank you, [Student Name], for such uplifting words. Let’s carry this thought with us as we go through the day and let it guide our actions. [News and Announcements] Anchor 1: Now, let’s move on to the latest updates. Here are some important news items and announcements for everyone. [Provide relevant updates and announcements.] Anchor 2: A quick reminder to all those participating in the Annual Day celebrations—please make sure to complete your event registrations by the end of this week. We can’t wait to see your amazing performances! [Motivational Segment] Anchor 1: It’s time for a motivational boost to inspire us all! Let’s remember, that every day is an opportunity to grow, learn, and work towards our goals. Anchor 2: Exactly! Every challenge we overcome makes us stronger, and every effort takes us one step closer to success. Let’s embrace today with energy and determination. [Special Performance] Anchor 1: Now, it’s time for something special! Please join me in welcoming [Student/Group Name], who will be performing a [type of performance, e.g., skit, song, or dance]. Let’s give them a big round of applause as they take the stage! Anchor 2: Sit back, relax, and enjoy the performance. Let’s show our appreciation for their creativity and effort! [Closing Remarks] Anchor 1: That was an amazing performance! A huge thank you to [Student/Group Name] for sharing their talent with us. Anchor 2: Absolutely! As we wrap up today’s assembly, let’s carry the positive energy and lessons we’ve learned with us. Anchor 1: Let’s continue supporting one another, facing challenges confidently, and making the most of every opportunity. Anchor 2: Thank you all for your participation and enthusiasm. Wishing everyone a productive and rewarding day ahead! Both Anchors: Goodbye, and have a wonderful day! This script is designed to make your school assembly both engaging and impactful, helping to foster positivity, build a sense of community, and create excitement. This guide provides everything you need to design a school assembly that resonates with students and staff alike. By integrating relevant news, motivational messages, and a well-prepared anchoring script, it inspires the audience, fosters positivity, and ensures the assembly is an event everyone will look forward to. Click for more latest Events news . Also get top headlines and latest news from India and around the world at News9. Chhaya Gupta, a lifestyle sub-editor specialising in fashion, food, relationships, travel, well-being, and spirituality, is a dedicated fashion enthusiast and avid traveller. With meticulous attention to detail, she stays abreast of the latest developments in major events across Indian cities and internationally. From life to style, she derives immense pleasure in covering a variety of subjects. With 1.5 years of experience, she has honed her skills while working at The Free Press Journal.SADC Announces Coup Leader Mnangagwa To Tour Gaborone, What Does He Want in Botswana?

Meals on Wheels spreads holiday joyThe Federal Government through the Federal Ministry of Agriculture and Food Security (FMAFS), has advised cocoa farmers to shun unethical practices in cocoa production leading to avoidable losses. The Minister of Agriculture and Food Security, Abubakar Kyari, gave the advice in Ibadan on Monday during the 60th anniversary of the Cocoa Research Institute of Nigeria (CRIN). Kyari, represented by FMAFS South-West Zonal Director, Mrs Olayinka Akeredolu, observed that cocoa farmers cut corners by rushing cocoa’s processing and production stages. “When cocoa is exported, they are tested and these sharp practices, which our people have done, are discovered. “The implication of this may be the rejection of our product and when they are rejected, it is a big loss to farmers, investors and Nigeria in general,” he said. Kyari said the FG would prefer things be done properly to enable farmers to gain from the efforts invested in producing the commodity. The minister urged cocoa farmers to seek counsel and interact with research institutes and extension agents whenever they have problems. The minister further urged the farmers to add value to their production to enjoy better income and gain from their efforts. “I will encourage them to continue to plant new cocoa when the ones they have are getting old; we have improved varieties in our research institute, which they can purchase and plant. “They need to adopt technology in the improvement of their production,” he said. He commended CRIN for its tremendous contribution and improvement over the years in developing its mandate crops, which include cocoa, kola, cashew, coffee, tea and plant plum. “The FG felicitate with you on your 60th anniversary and encourage you to continue to do more to attain fulfilment of your mandate and contribution to the GDP of the country,” he said. Earlier, CRIN Executive Director, Dr Patrick Adebola, commended the FG as well as the staff of the institute for their support and commitment. Adebola reaffirmed the institute’s commitment to leading the change in agriculture innovation, leveraging science and technology to enhance productivity and improve farmers’ livelihood in Nigeria. The News Agency of Nigeria (NAN) reports the presentation of awards as the occasion’s highlight.

Natixis Advisors LLC Purchases 1,177 Shares of RenaissanceRe Holdings Ltd. (NYSE:RNR)

Prospect Capital Corporation Hosting Upcoming Webinar: "Preferred Stock as a Low Volatility, Downside Protected, and Income Generating Asset Class”

TOKYO and CAMBRIDGE, Mass. , Dec. 4, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts , CEO: Christopher A. Viehbacher , "Biogen") announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI ® " (lecanemab) for the treatment of early Alzheimer's disease (AD)*. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils**), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved and being marketed in the U.S., Japan , China , South Korea , Hong Kong , Israel , the United Arab Emirates, and Great Britain . LEQEMBI's approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results. 1,2 Approximately 1.3 million people in Mexico are estimated to suffer from AD, accounting for 60-70% of all dementia diagnoses. 3 AD most commonly affects individuals over the age of 65. 3 Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai and Biogen will co-commercialize and co-promote LEQEMBI in Mexico . * Collectively referred to mild cognitive impairment due to AD or mild AD dementia. ** Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition. 4 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction. 5 Notes to Editors 1. About lecanemab (LEQEMBI ® ) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved and being marketed in the U.S., Japan , China , South Korea , Hong Kong , Israel , the United Arab Emirates and Great Britain for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). The treatment's approvals in these countries was based on Phase 3 data from Eisai's global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. 1,2 The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall. Lecanemab is under regulatory review in 16 countries and regions, including the European Union. In November 2024 , the treatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022 , the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis , is ongoing and includes lecanemab as the backbone anti-amyloid therapy. 2. About the Collaboration between Eisai and Biogen for AD Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. 3. About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007 . The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015 . 4. About Eisai Co., Ltd. Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care ( hhc ) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe , Middle East , Africa , Russia , Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X ( global and U.S ), LinkedIn (for global , U.S. and EMEA ) and Facebook ( global ). 5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at www.biogen.com . Follow Biogen on social media – Facebook , LinkedIn , X , YouTube . Biogen Safe Harbor This news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements. References View original content to download multimedia: https://www.prnewswire.com/news-releases/leqembi-lecanemab-approved-for-the-treatment-of-early-alzheimers-disease-in-mexico-302322515.html SOURCE Eisai Inc.

Tulsi Gabbard, Trump’s pick for intel chief, faces questions on Capitol Hill amid Syria falloutTrump vows to pursue executions after Biden commutes most of federal death rowDow Jones closes above 45,000 for the first time after Jerome Powell says economy is 'remarkably good'